STOCKS TELEGRAPH

Tag: NASDAQ: FBIO

  • 3 Stocks Worth Watching Today: Cardiol Therapeutics (CRDL), Fortress Biotech (FBIO), Dogwood Therapeutics (DWTX)

    3 Stocks Worth Watching Today: Cardiol Therapeutics (CRDL), Fortress Biotech (FBIO), Dogwood Therapeutics (DWTX)

    Investor attention in the healthcare sector continues to be shaped by the balance between near-term clinical catalysts and long-term commercial potential. While short-term price action can be influenced by sentiment and liquidity conditions, sustained valuation growth is typically driven by meaningful clinical validation. This dynamic keeps focus firmly on programs advancing through pivotal stages of development.

    Cardiol Therapeutics Inc. (CRDL)

    Cardiol Therapeutics Inc. (NASDAQ: CRDL) is entering an increasingly important stage of development as growing scientific validation supports the advancement of its lead cardiovascular therapy. For clinical-stage biotech companies, publication in respected peer-reviewed journals can significantly strengthen credibility with both investors and the broader medical community.

    Market Momentum

    As of May 8, 2026, CRDL closed at $1.32, up 1.54%, with trading volume reaching 578,846 shares compared to an average volume of 686,648 shares. The company currently holds a market capitalization of $147.418M and a beta of 0.43, reflecting relatively moderate volatility for a small-cap biotech stock. Shares continue to trade within their 52-week range of $0.8800 to $1.71, while the 1-year target estimate of $7.40 suggests substantial upside potential tied to future clinical milestones.

    Clinical Validation

    Cardiol recently announced that Phase II results for CardiolRx™ in recurrent pericarditis will be published in the Journal of the American Heart Association. The study demonstrated rapid and sustained reductions in pain and inflammation, particularly among patients with more severe disease at baseline. Researchers also observed fewer annual recurrence episodes, alongside favorable safety and tolerability findings.

    Impact on Late-Stage Development

    The Phase II data continues to support the advancement of the ongoing Phase III MAVERIC trial, which has now enrolled more than 75% of participants. Importantly, the earlier findings also helped shape the design of the pivotal study, strengthening the clinical rationale behind CardiolRx™’s development strategy.

    Outlook

    With a peer-reviewed publication adding external validation to its clinical profile, Cardiol appears increasingly well-positioned as it advances toward key regulatory and commercialization milestones.

    Fortress Biotech Inc (FBIO)

    Fortress Biotech Inc (NASDAQ: FBIO) started the day on May 08, 2026, with a price decrease of -0.42% at $2.39. During the day, the stock rose to $2.44 and sank to $2.36. Taking a long-term approach, FBIO posted a 52-week range of $1.60-$4.53.

    The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 62.98%. Meanwhile, its Annual Earnings per share during the time was 62.98%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is -900.00%. This publicly-traded company’s shares outstanding now amount to $31.36 million, simultaneously with a float of $24.35 million. The organization now has a market capitalization of $76.96 million.

    Dogwood Therapeutics Inc (DWTX)

    As of May 08, 2026, Dogwood Therapeutics Inc (NASDAQ: DWTX) got off with the flyer as it spiked 5.77% to $1.65. During the day, the stock rose to $1.66 and sank to $1.55. Taking a long-term approach, DWTX posted a 52-week range of $1.28-$9.50.

    In the past 5-year timespan, the Healthcare sector firm’s annual sales growth was 25.53%. Meanwhile, its Annual Earnings per share during the time was 25.53%.  Nevertheless, the stock’s Earnings Per Share (EPS) this year is 85.69%. This publicly-traded company’s shares outstanding now amount to $33.40 million, simultaneously with a float of $33.40 million. The organization now has a market capitalization of $55.11 million.

  • Here’s Top 25 Biotech Stocks For September 2020

    Here’s Top 25 Biotech Stocks For September 2020

    One thing constant in the world is change. As time passes there are many industries that are undergoing changes as they expand their businesses and bring new innovations. One of the industries that are known for their constant change is the biotechnology industry.

    The biotech industry is continuously changing in every aspect of daily existence with new technological breakthroughs and advancements in knowledge. Companies are constantly striving to bring new medicines and vaccines to deal with the diagnosis.

    Let’s have a look at the top 25 biotech companies which are continuously adding new trends in the market:

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) shares were trading up 171.59% at $34.22 at the time of writing on Monday.

    Aimmune Therapeutics Inc. (NASDAQ: AIMT) share price went from a low point around $10.09 to briefly over $37.00 in the past 52 weeks, though shares have since pulled back to $34.22. AIMT market cap has remained high, hitting $2.13B at the time of writing, giving it a price-to-sales ratio of more than 3550.

    If we look at the recent analyst rating AIMT, Cowen initiated coverage on AIMT shares with an Outperform rating. Aimmune Therapeutics recently disclosed it has signed an agreement with Nestle S.A. As per the agreement, Nestle will pay $34.50 per share in an all-cash transaction.

    Akcea Therapeutics Inc. (AKCA) last closed at $18.28, in a 52-week range of $8.00 to $22.79. It has been disclosed yesterday that Ionis Pharmaceutical has bought the 24% shares of Akcea it hasn’t owned earlier for $18.15 per share in cash. This acquisition is one step forward to make a strong and efficient organization that gives benefits to all shareholders.

    Capricor Therapeutics Inc. (NASDAQ: CAPR) Shares headed rising, higher as much as 14.64% after Capricor Therapeutics to Present at The LD 500 Virtual Conference. Capricor market capitalization is 115.11 million. The most recent rating by Maxim Group, on December 26, 2018, is at a Hold.

    Capricor Therapeutics, a clinical-stage biotechnology company has disclosed earlier that the US Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for a Phase 2 clinical trial of CAP-1002 in COVID-19 patients.

    Apellis Pharmaceuticals Inc. (APLS) stock soar by 14.74% to $30.83. The most recent rating by ROTH Capital, on July 20, 2020, is at a Buy. Its stock fluctuated between the 52-weeks low range of $16.85 and a 52-weeks high range of $45.04. It has moved up 82.97% from its 52-weeks low and moved down -31.55% from its 52-weeks high.

    Xeris Pharmaceuticals Inc. (NASDAQ: XERS) rose 10.71% after gaining more than $0.45 on Monday. Xeris, a specialty pharmaceutical company disclosed August 26, 2020, that the Compensation Committee of Xeris’ Board of Directors awarded non-qualified stock options for an aggregate of 500 share of its common stock to 1 new employee under the Inducement Equity Plan of Xeris.

    Xeris share price went from a low point around $1.42 to briefly over $12.29 in the past 52 weeks, though shares have since pulled back to $4.71. It has traded up $231.34% from its 52-weeks low and has traded down -61.72% from its 52-weeks high.

    9 Meters Biopharma Inc. (NASDAQ: NMTR) shares headed rising, higher as much as 7.73%. It has disclosed Monday that it has decided to form the scientific advisory board (SAB). The SAB includes an acclaimed group of six experts in the gastroenterology field with sub-specialties in celiac disease, inflammatory bowel disease (IBD), and functional GI diseases. 9 Meters have gained +0.05 during its trading on Monday. It has moved up 76.17% and moved down -49.46% from its 52-weeks low and high range, respectively.

    VBI Vaccines Inc. (NASDAQ: VBIV) rose 6.77% after gaining more than $0.27 on Monday. VBI Vaccines Presents Phase 3 Sci-B-Vac® Data at EASL 2020. During the presentation, Professor of Paediatrics at the University of Bristol, UK, and principal investigator of the CONSTANT Phase 3 clinical study, Adam Finn, M.D., Ph.D., revealed the encouraging points of hepatitis B antibodies. VBI Vaccines traded up 815.15% from its 52-weeks low and traded down -38.53% from its 52-weeks high.

    CymaBay Therapeutics Inc. (NASDAQ: CBAY) rose 5.37% after gaining more than $0.33 on Monday. It has disclosed the result of Phase 2 study of seladelpar in patients with primary biliary cholangitis (PBC). The data presented at electronic presentation showed the safety and efficacy of seladelpar over 1 year of open level treatment. These findings suggest that seladelpar treatment in a high-risk PBC patient population promotes clinically significant improvement.

    BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX) rose 4.53% after gaining more than $0.18 on Monday. BioCryst Inc disclosed Monday it has received Orphan Drug Desigantion from FDA for its oral Factor D inhibitor, BCX9930. It is used for the treatment paroxysmal nocturnal hemoglobinuria (PNH). It has moved up as its announced it has received the $44 million  National Institute of Allergy and Infectious Diseases (NIAID). This amount is awarded to BCRX by NIAID to support the development of galidesivir.

    ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Shares headed rising, higher as much as 4.24%. The most recent rating by Raymond James, on August 25, 2020, is at an Outperform. ACADIA Inc has announced earlier that it has bought CerSci Therapeutics.

    Immunomedics Inc. (IMMU) stock soar by 6.37% to $44.56. The most recent rating by Barclays, on May 05, 2020, is at an Overweight. Immunomedics stock has fluctuated between the 52-weeks low and high range of $8.80-$44.91, respectively.

    Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) last closed at $114.22, in a 52-week range of $72.67 to $121.50. Analysts have a consensus price target of $141.47.

    Seres Therapeutics Inc. (NASDAQ: MCRB) stock soar by 8.21% to $26.49.  It has moved upward 951.19% from its 52-weeks low and moved down -19.73% from its 52-weeks high. The most recent rating by Piper Sandler, on August 18, 2020, is at an Overweight.

    Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) last closed at $29.51 after gaining +2.54 on Monday. It has a 52-week range of $12.99 to $27.97. It has moved up 127.17% and 5.51% from its 52-weeks low and high, respectively. Analysts have a consensus price target of $32.88.

    Geron Corporation (NASDAQ: GERN) Shares headed rising, higher as much as 6.22%. The most recent rating by Stifel, on August 03, 2020, is at a Buy.

    Sesen Bio Inc. (NASDAQ: SESN) rose 6.19% after gaining more than $0.06 on Monday. SESN’s stock has changed between the 52-weeks low range of $0.37 and a high range of $1.52. It has moved up and moved down 178.38%, -33.12% from its 52-weeks low and high, respectively.

    Kadmon Holdings Inc. (NYSE: KDMN) last closed at $5.00, in a 52-week range of $2.04 to $5.50. It has traded up 145.10% from its 52-weeks low and traded down -9.09% from its 52-weeks high. Looking at its liquidity, its current ratio is 6.20.

    Evofem Biosciences Inc. (EVFM) stock soar by 6.07% to $3.32 after Evofem Biosciences to Participate in Four Upcoming Investor Conferences. The most recent rating by Morgan Stanley, on August 20, 2020, is at an Equal-weight.

    MacroGenics Inc. (NASDAQ: MGNX) Shares headed rising, higher as much as 6.01%. The most recent rating by Citigroup, on August 03, 2020, is at a Neutral.

    Iovance Biotherapeutics Inc. (NASDAQ: IOVA) last closed at $33.33, in a 52-week range of $17.67 to $41.49. Analysts have a consensus price target of $47.08.

    Surface Oncology Inc. (NASDAQ: SURF) stock soar by 5.01% to $6.50. The most recent rating by Wedbush, on August 28, 2020, is at an Outperform.

    Fortress Biotech Inc. (NASDAQ: FBIO) Shares headed rising, higher as much as 4.63% after LD Micro — 360 Companies Set to Present this Week. The most recent rating by B. Riley FBR, on December 18, 2019, is at a Buy.

    Synthetic Biologics Inc. (SYN) last closed at $0.64, in a 52-week range of $0.25 to $0.75. It has moved up 153.17% from its 52-weeks low and moved down -14.87% from its 52-weeks high.

    Zogenix Inc. (NASDAQ: ZGNX) stock soar by 4.37% to $23.67. The most recent rating by Raymond James, on August 25, 2020, is at an Mkt perform. ZGNX has traded up and down 42.16% and -58.63% from its 52-weeks low and high range.

    Dynavax Technologies Corporation (NASDAQ: DVAX) rose 4.18% after gaining more than $0.24 on Monday. Dynavax to Present at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference.